Limits...
Verification of tomotherapy dose delivery.

Pelagade SM, Paliwal BR - J Med Phys (2009)

Bottom Line: The agreement in absolute point dose was 1.19 +/- 0.79%, 1.91 +/- 1.39%, 2.14 +/- 1.3%, 1.3 +/- 0.73% and 1.67 +/- 1.5% for head and neck, prostate, pelvis-abdomen sites, and for all other sites.The spatial agreement between the calculated and the measured film dose distributions was evaluated using the gamma metric distribution.The average frequency versus gamma interval was plotted as a bar graph to quantify the gamma index variation inside the region of interest for each body site.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Physics, The Gujarat Cancer & Research Institute, NCH Campus, Asarwa, Ahmedabad-380016, India.

ABSTRACT
Seventy-one patient-specific delivery quality assurance (DQA) plans for the Tomotherapy HI-ART II helical tomotherapy system (TomoTherapy, Inc., Madison, WI, USA) were measured using film and ion chamber. The agreement in absolute point dose was 1.19 +/- 0.79%, 1.91 +/- 1.39%, 2.14 +/- 1.3%, 1.3 +/- 0.73% and 1.67 +/- 1.5% for head and neck, prostate, pelvis-abdomen sites, and for all other sites. The spatial agreement between the calculated and the measured film dose distributions was evaluated using the gamma metric distribution. The average frequency versus gamma interval was plotted as a bar graph to quantify the gamma index variation inside the region of interest for each body site.

No MeSH data available.


The left hand side image shows 3D rendering of the phantom. The right hand side image shows cross-section view that exposes the location of the ion chamber
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2807687&req=5

Figure 0001: The left hand side image shows 3D rendering of the phantom. The right hand side image shows cross-section view that exposes the location of the ion chamber

Mentions: In this study we analyzed DQA verification plans for 71 patients (10 cases for head and neck, 18 for prostate, 12 for lung, six for pelvis-abdomen and 25 for “others”) treated using the Tomotherapy HI-ART II system. The patients were categorized according to their disease sites: head and neck, prostate, lung, pelvis-abdomen and “others”. Measurements were recorded using spiral phantom as shown in Figure 1.


Verification of tomotherapy dose delivery.

Pelagade SM, Paliwal BR - J Med Phys (2009)

The left hand side image shows 3D rendering of the phantom. The right hand side image shows cross-section view that exposes the location of the ion chamber
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2807687&req=5

Figure 0001: The left hand side image shows 3D rendering of the phantom. The right hand side image shows cross-section view that exposes the location of the ion chamber
Mentions: In this study we analyzed DQA verification plans for 71 patients (10 cases for head and neck, 18 for prostate, 12 for lung, six for pelvis-abdomen and 25 for “others”) treated using the Tomotherapy HI-ART II system. The patients were categorized according to their disease sites: head and neck, prostate, lung, pelvis-abdomen and “others”. Measurements were recorded using spiral phantom as shown in Figure 1.

Bottom Line: The agreement in absolute point dose was 1.19 +/- 0.79%, 1.91 +/- 1.39%, 2.14 +/- 1.3%, 1.3 +/- 0.73% and 1.67 +/- 1.5% for head and neck, prostate, pelvis-abdomen sites, and for all other sites.The spatial agreement between the calculated and the measured film dose distributions was evaluated using the gamma metric distribution.The average frequency versus gamma interval was plotted as a bar graph to quantify the gamma index variation inside the region of interest for each body site.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Physics, The Gujarat Cancer & Research Institute, NCH Campus, Asarwa, Ahmedabad-380016, India.

ABSTRACT
Seventy-one patient-specific delivery quality assurance (DQA) plans for the Tomotherapy HI-ART II helical tomotherapy system (TomoTherapy, Inc., Madison, WI, USA) were measured using film and ion chamber. The agreement in absolute point dose was 1.19 +/- 0.79%, 1.91 +/- 1.39%, 2.14 +/- 1.3%, 1.3 +/- 0.73% and 1.67 +/- 1.5% for head and neck, prostate, pelvis-abdomen sites, and for all other sites. The spatial agreement between the calculated and the measured film dose distributions was evaluated using the gamma metric distribution. The average frequency versus gamma interval was plotted as a bar graph to quantify the gamma index variation inside the region of interest for each body site.

No MeSH data available.